GSK’s Belimumab shows significant improvement in renal function in the largest Lupus Nephritis (LN) clinical study

In the most extensive study to date, GSK’s Belimumab (alongside Standard therapy) vs. placebo showed a significant improvement in LN renal response, such as renal filtration and urine protein creatinine. Moreover, Belimumab also demonstrated a favorable safety profile. The results were presented at the 2020 EULAR e-congress.

Source: https://ard.bmj.com/content/79/Suppl_1/103

Source: https://clinicaltrials.gov/ct2/show/NCT01639339

Lupus Blog Articles: Lupus lorem ipsum dolor sit amet est requiem deste natur.

Anifrolumab (Saphnelo) listed in SK

Read

Belimumab (Benlysta) listed in AB, NL & NIHB

Read

Belimumab (Benlysta) listed in ON

Read